<DOC>
	<DOCNO>NCT00765999</DOCNO>
	<brief_summary>The objective study ass long-term safety linaclotide administer patient chronic constipation ( CC ) irritable bowel syndrome constipation ( IBS-C )</brief_summary>
	<brief_title>An Open-Label , Long-Term Safety Study Linaclotide Patients With Chronic Constipation Irritable Bowel Syndrome With Constipation</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Patients must enter study LINMD01 LINMD31 minimum complete pretreatment period complete one follow study : MCP103004 , MCP103005 , MCP103201 , MCP103202 Sexually active patient childbearing potential agree use birth control Females childbearing potential must negative urine pregnancy test prior dose Lactating female must agree breastfeed Patient must meet protocol criterion chronic constipation ( CC ) irritable bowel syndrome constipation ( IBSC ) Patient must use protocoldefined prohibited medicine Patient planning receive investigational drug time study Patient unresolved adverse event ( AE ) clinically significant find physical examination , 12lead electrocardiogram ( ECG ) , clinical laboratory test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Constipation</keyword>
	<keyword>Chronic Constipation</keyword>
	<keyword>Irritable Bowel Syndrome With Constipation</keyword>
	<keyword>Linaclotide</keyword>
</DOC>